Engage Bio is developing mRNA immunotherapies to eliminate cancer. Our founders have deep experience in immunotherapy development, including four drugs in the clinic, and in building mRNA therapeutics platforms. In the last four months, we have moved from concept to fully working drugs which have eliminated human tumors in mice. We achieve this by delivering mRNA directly to the tumors, providing instructions for these cells to make and gradually release our drugs. This local therapy allows us to completely eliminate the cancer while sparing distant healthy tissues.
Kathryn has 12 years of experience engineering proteins for improved properties. She spent 5 years as a key early scientist at Harpoon Therapeutics, where she developed bispecific immunotherapies and protease activated immunotherapies. She has helped develop multiple drugs that are currently in the clinic to treat various cancers and has multiple patents and patent applications.
Co-Founder, Engage Bio Former VP of Development Operations at Rejuvenation Technologies Co-founder and COO of Luminist Labs (Acquired by DiscernDx)